维立西呱对射血分数降低的心力衰竭患者疗效研究OA

Objective To observe the effect of vericiguat on improvement of ventricular remodeling in-dex,serum N-terminal pro-B-type natriuretic peptide(NT-proBNP)level and New York Heart Association(NYHA)cardiac function classification in patients with heart failure with reduced ejection fraction(HFrEF).Methods A total of 100 patients with HFrEF who were admitted to the hospital from January 2023 to March 2023 were selected for a prospective study,and they were randomly divided into the observation group and the control group,with 50 patients in each group.The control group was given shakubatravalsartan sodium tab-lets,metoprolol succinate sustained-release tablets,spironolactone tablets,dapagliflozin tablets combined with furosemide orally,while the observation group was given vericiguat orally in addition to the control group.A total of three months were followed up,and the changes in NT-proBNP,left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),and NYHA cardiac function classification before and after treatment were compared between the two groups.Results Compared with before treatment,LVEF,LVESD,LVEDD and NT-proBNP in the two groups were significantly improved after treatment,and the differences were statistically significant(P<0.05).There was no significant difference in LVEF,LVESD,LVEDD and NT-proBNP between the two groups before and after treatment(P>0.05).The total effective rate of the patients in the observation group[94.0%(47/50)]was significantly higher than that in the control group[76.0%(38/50)],and the difference was statistically signif-icant(P<0.05).Conclusion Vericiguat has a good curative effect on HfrEF,which can improve patients'ex-ercise tolerance and improve NYHA cardiac function classification.